.
.
.
.

Coronavirus: India begins first human trials of vaccine

Published: Updated:

India began its first human trials of a novel coronavirus vaccine candidate as the world’s second-most populous country recorded nearly 49,000 new cases.

The additional infections take India’s total to more than 1.3 million on Saturday, with surges seen in a quarter of the country’s 36 states and union territories.

India has tallied 31,358 deaths, including 757 in the last 24 hours. It has reported a much lower death rate than the world’s two other worst-hit countries, the United States and Brazil. Johns Hopkins University showed that the U.S. has more than 4.1 million cases, while Brazil has a caseload of nearly 2.3 million.

The All India Institute of Medical Sciences, a premier teaching hospital in the capital of New Delhi, says it has administered the first dose of a trial COVID-19 vaccine on Friday.

An elderly Indian reacts as a staff member checks his body temperature before allowing him into an eatery in Bengaluru, India on May 30, 2020. (AP)
An elderly Indian reacts as a staff member checks his body temperature before allowing him into an eatery in Bengaluru, India on May 30, 2020. (AP)

The candidate vaccine, Covaxin, is among nearly two dozen that are in human trials around the world. AIIMS is among the 12 sites selected by the Indian Council for Medical Research for conducting the two-phase randomized, double-blind, placebo-controlled clinical trials of Covaxin.

Countries are making giant bets on various vaccine candidates, entering into purchasing agreements with pharmaceutical companies for delivery if and when regulators deem the doses safe and effective.

Read more:

Coronavirus: 97 medical workers in Yemen die from COVID-19 says report

Fire breaks out at Iranian compound housing senior IRGC commanders

‘It is my belief that we need to collapse the regime,’ US Senator Cruz says on Iran